相关实验视频

Updated: Jun 5, 2025

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

对诱导化疗的反应作为局部发达的头部和部状细胞癌的预后指标

Francesca Huwyler¹, Roland Giger², Ruben Bill¹

¹Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Journal of cancer research and clinical oncology

|December 3, 2024

概括

诱导化疗 (IC) 有效地治疗晚期头部和部状细胞癌 (HNSCC). 患者对IC的反应预测了生存结果,特别是在喉和喉下癌症.

科学领域:

在瘤学瘤学.
头部和部癌症研究研究
化疗疗的有效性化疗的有效性

背景情况:

诱导化疗 (IC) 是局部发达的头部和部状细胞癌 (HNSCC) 的治疗选择.
评估IC反应对患者存活率的影响对于治疗规划至关重要.

研究的目的:

评估诱导化疗 (IC) 反应与局部发达HNSCC患者的生存结果之间的相关性.
确定IC反应是否是HNSCC.生存的预后因素.

主要方法:

对48名局部发达HNSCC患者进行了回顾性单中心研究,这些患者接受了IC.
用放射学评估瘤对IC的反应;使用卡普兰-梅尔曲线和考克斯回归分析生存结果.
根据瘤部位 (喉,下喉,口腔,口腔) 和IC反应 (响应者与非响应者) 分类的患者.

主要成果:

在33名可评估患者中,69.7%的人通过IC实现了>=30%的瘤减少;整体瘤控制率为97%.
两年无事件生存率 (EFS) 为53.1%,整体生存率 (OS) 为63.6%,无复发性生存率 (RFS) 为62.5%.
对IC的不响应与喉/鼻HNSCC的预后较差有显著的相关性,但对口腔/鼻瘤没有显著的相关性.

结论:

诱导化疗 (IC) 在局部发达的HNSCC.中显示出高疗效.
对IC的反应是生存的重要预后指标,特别是在喉和下癌中.

关键词:

化疗反应对化疗的反应.头部和部状细胞癌瘤诱导化疗是一种诱导化疗.预测生存率的预测

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...